OOIR: Observatory of International Research

Papers

(The H4-Index of Acta Pharmaceutica Sinica B is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Why 90% of clinical drug development fails and how to improve it?	555
Gasdermin D in pyroptosis	325
Long non-coding RNAs: From disease code to drug role	289
The biology, function, and applications of exosomes in cancer	267
Metal-organic frameworks for advanced drug delivery	257
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies	242
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma	240
Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways	231
Crystal structure of SARS-CoV-2 papain-like protease	222
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy	216
New opportunities and challenges of natural products research: When target identification meets single-cell multiomics	182
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway	180
Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies	170
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management	158
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis	158
Ginsenosides in Panax genus and their biosynthesis	152
Antibody–drug conjugates: Recent advances in linker chemistry	151
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy	149
Traditional Chinese medicine in COVID-19	149
Recent advances in drug delivery systems for targeting cancer stem cells	148
Current approaches of nanomedicines in the market and various stage of clinical translation	146
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives	146
Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications	145
Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome	140
Advances and challenges in the treatment of esophageal cancer	136

Small interfering RNA for cancer treatment: overcoming hurdles in delivery	135
Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation	133
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies	132
Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses	131
Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1	130
The cGAS–STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy	126
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo	125
Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1	123
Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening	122
The progress and perspective of nanoparticle-enabled tumor metastasis treatment	121
Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy	118
Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5	118
Emerging role of natural products in cancer immunotherapy	118
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges	117
Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers	117
Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years	116
The influence of the gut microbiota on the bioavailability of oral drugs	116
Recent advances in drug delivery applications of cubosomes, hexosomes, and solid lipid nanoparticles	115
Biological drug and drug delivery-mediated immunotherapy	114
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy	107
Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy	106
An update on oral drug delivery via intestinal lymphatic transport	106
Cell membrane coated-nanoparticles for cancer immunotherapy	102
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator	101
Integrins as attractive targets for cancer therapeutics	101
Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation	100
Carbohydrate-based drugs launched during 2000−2021	98
Recent developments on PET radiotracers for TSPO and their applications in neuroimaging	94
Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design	93
GSH-sensitive polymeric prodrug: Synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine	92
Recent progress in sono-photodynamic cancer therapy: From developed new sensitizers to nanotechnology-based efficacy-enhancing strategies	90
Recent advances in nanomedicines for the treatment of ischemic stroke	89
Cell membrane-derived vesicles for delivery of therapeutic agents	88
Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle	87
A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer	87
Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy	87
Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential	87
Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment	85
Ginsenoside Rg1 ameliorates blood–brain barrier disruption and traumatic brain injury via attenuating macrophages derived exosomes miR-21 release	85
The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment	83
Target-based anticancer indole derivatives and insight into structure‒activity relationship: A mechanistic review update (2018–2021)	81
Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines	80
Pathophysiology of obesity and its associated diseases	80
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs	78
A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine	78
Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies	77
Insight into chemical basis of traditional Chinese medicine based on the state-of-the-art techniques of liquid chromatography−mass spectrometry	76
Recent developments in the medicinal chemistry of single boron atom-containing compounds	76
A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives	74
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers	74

Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era